45 results about "Vasodilator agents" patented technology

Disclosed are derivatives of isosorbid mononitrate and pharmaceutically acceptable salts thereof which have a vasodilator activity with a reduced tolerance effect, having the general formula (I) wherein A and B represent independently any of the groups NO2 and-CO-R, Z being an atom of oxygen or sulfur, and R being optionally substituted C1-C4 alkyl, aryl or aralkyl group or the group (a) wherein R<1> is hydrogen or optionally substituted C1-C4 alkyl, aryl or aralkyl group,so that always either A or B is NO2 but never both at the same time, when Z is a sulfur atom R is optionally substituted C1-C4 alkyl, aryl or aralkyl group, and when Z is an oxygen atom R is the group (a).

The invention is directed to a method of administering hydrogen sulfide (H2S) slowly and sustainably to an individual in need thereof comprising administering an effective amount of a compound represented by the following structural formula:or a pharmaceutically acceptable salt thereof.

The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.

The invention discloses a traditional Chinese medicine monomer composition for antagonizing lung injury. The traditional Chinese medicine monomer composition comprises main active ingredients such asquercetin, glycyrrhizic acid and ferulic acid. The invention also discloses a use of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition can adjust the respiratory immune system through activating the cAMP-dependent CFTR, prevent the pathological damage caused by the excessive immune response caused by the loss or inhibition of the immune tolerance mechanism, inhibit the lung fibrosis and promote the repair of damaged cells into normal cells.

The invention provides a method for analyzing and identifying dihydroquercetin in larches by capillary electrophoresis-mass spectrometry (CE-MS). The method includes the steps: (1) preparing standardsolution of pure dihydroquercetin, injecting a sample into a capillary electrophoresis apparatus and performing analysis in a mass spectrometer to obtain a mass spectrum; (2) drawing a standard curveand calculating the lowest detection limit; (3) acquiring the mass spectrum of the sample by a method in the step (1) and calculating sample injection recovery rate; (4) identifying the dihydroquercetin in the larches according to sample chromatographic peak and characteristic daughter ion information; (5) quantitatively analyzing the dihydroquercetin in the larches according to the standard curve. The method has the advantages of simplicity in operation, time-saving property, high detection efficiency, good repeatability and the like. The needed sample is less in dosage, detection results areaccurate and reliable, and the method is an excellent method for qualitatively and quantitatively analyzing the dihydroquercetin in the larches.

The invention discloses a novel application of a medicine of 1-[2-(3-amino-6-methylthiophene [2,3-b] quinolyl)] ethyl ketone. The new application of the compound (PU-14) disclosed by the invention is an application in the preparation of a vasodilator agent medicine. The PU14 has an effect of directly relaxing blood vessels by adopting in vitro thoracic aorta and mesenteric artery models in mice and rats. The effect is similar to that of acetyl choline, and has endothelial dependence and NO dependence; the action can be blocked off by an NOS inhibitor L-NAME and a cyclooxygenase inhibitor indometacin part; and meanwhile, in vivo and in vitro research results both prove that the UT-B gene deletion or function deficiency can play a role in relaxing blood vessels by adjusting the interaction between L-Arg-NOS-NO and L-Arg-arginase-urea systems.

The invention relates to the use of a composition comprising dihydroquercetin, alpha-tocopherol, and optionally bisabolol and / or a compound of formula (I) for use in the treatment of leishmaniasis, especially cutaneous leishmaniasis. The invention further relates to the use of such a composition for treating inflammation induced by leishmaniasis, especially cutaneous leishmaniasis. The invention also relates to a method for treating leishmaniasis, especially cutaneous leishmaniasis, and / or the associated inflammation by administering an effective amount of a composition comprising dihydroquercetin, bisabolol, alpha-tocopherol and optionally bisabolol and / or a compound of formula (I) to a subject in need thereof.